Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash & Equivalents (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Cash & Equivalents data on record, last reported at $4.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 55.15% year-over-year to $4.6 million; the TTM value through Sep 2025 reached $4.6 million, up 55.15%, while the annual FY2024 figure was $2.2 million, 2.3% up from the prior year.
  • Cash & Equivalents reached $4.6 million in Q3 2025 per NWBO's latest filing, up from $4.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $15.2 million in Q4 2021 and bottomed at $1.4 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $5.1 million, with a median of $4.3 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 877.49% in 2021, then plummeted 70.52% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $15.2 million in 2021, then plummeted by 54.08% to $7.0 million in 2022, then crashed by 69.48% to $2.1 million in 2023, then rose by 2.3% to $2.2 million in 2024, then surged by 109.66% to $4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $4.6 million in Q3 2025, $4.3 million in Q2 2025, and $2.8 million in Q1 2025.